Pharmaceutical companies sell to a surprisingly complex web of customers, and the person who swallows the pill is rarely the one writing the check. The real customers include wholesale distributors, hospitals, government programs, pharmacies, insurance intermediaries, and, increasingly, patients themselves. Each plays a distinct role in how drugs move from factory to medicine cabinet.
Wholesale Distributors: The Biggest Buyers
The single largest customers of pharmaceutical companies are wholesale distributors, the middlemen who purchase drugs in bulk and deliver them to pharmacies, hospitals, and clinics across the country. In the U.S., this market is dominated by three companies: McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health. Together, they control over 90% of the prescription drug distribution market by revenue. That concentration has only grown over time, rising from about 87% in 2013 to roughly 95% by 2018, where it has largely remained.
These distributors are the pharmaceutical industry’s primary revenue channel. When a drugmaker ships product, it is almost always headed to one of these three warehouses before it reaches anyone else. The distributors then resell to tens of thousands of pharmacies and health systems, earning thin margins on enormous volume.
Hospitals and Group Purchasing Organizations
Hospitals are major pharmaceutical customers, but most don’t negotiate drug prices on their own. Instead, they join group purchasing organizations (GPOs), which pool the buying power of hundreds or thousands of hospitals to negotiate lower prices from manufacturers and distributors. A hospital that switches from a smaller GPO to a larger one can cut its supply expenses by nearly 5% per discharge, which translates to annual savings of over $1.2 million for an average facility.
GPOs don’t just save money. They also shape which drugs hospitals stock, effectively deciding which products get steady, high-volume orders. For pharmaceutical companies, winning a GPO contract means guaranteed access to a large network of hospitals. Losing one can mean being shut out of entire regions.
Government Programs
Federal and state governments are among the largest payers for prescription drugs in the world. In the U.S., the federal government sponsors about 31% of all national health spending, while state and local governments account for another 16%. Medicaid alone reached $931.7 billion in total spending in 2024.
Medicare, the federal program covering Americans 65 and older, has become an especially powerful customer. Starting January 1, 2026, Medicare will for the first time pay negotiated prices on ten high-cost drugs, a process that is expected to expand to more medications in coming years. For pharmaceutical companies, government programs represent enormous, stable revenue, but also come with price controls, mandatory rebates, and growing regulatory leverage that private buyers don’t have.
Pharmacy Benefit Managers
Pharmacy benefit managers, or PBMs, sit between pharmaceutical companies and the patients who use their drugs. They build the formularies (lists of covered medications) for insurance plans, negotiate rebates with drugmakers, and set up the pharmacy networks that policyholders can use. If a PBM decides not to include a drug on its formulary, that drug is effectively invisible to millions of insured patients.
This gives PBMs extraordinary leverage. A pharmaceutical company that wants its medication placed on a preferred tier, where patients pay lower copays and are more likely to fill prescriptions, has to offer the PBM financial incentives. The most common form is manufacturer rebates: the drugmaker pays the PBM a percentage of the drug’s list price in exchange for favorable formulary placement. PBMs also profit through spread pricing, where they reimburse the pharmacy one amount for a drug while charging the insurance plan a higher amount and keeping the difference. PBMs are not required to publicly disclose how much of each rebate they retain, a longstanding source of controversy in the industry.
While PBMs technically represent insurers and employers, their control over which drugs patients can access and afford makes them one of the most influential customers pharmaceutical companies must serve.
Retail and Specialty Pharmacies
Retail pharmacies like CVS, Walgreens, and thousands of independent stores are the most visible link between pharmaceutical companies and patients. They purchase drugs either directly from manufacturers or through wholesale distributors, then dispense them to individuals with prescriptions.
Specialty pharmacies are a distinct and fast-growing segment. These pharmacies handle complex, high-cost medications like biologics and treatments for rare diseases. Unlike retail pharmacists, specialty pharmacists provide extensive patient education, monitor adherence, manage drug storage requirements, and call patients who miss refills. They dispense products directly to patients, often by mail, and focus on therapies that require careful handling or close clinical oversight. For pharmaceutical companies developing biologics or orphan drugs, specialty pharmacies are often the primary distribution channel.
Physicians as Decision-Making Customers
Doctors don’t typically buy drugs themselves, but they are arguably the most important customer pharmaceutical companies market to. A physician’s prescribing decision determines which products patients receive, which in turn drives a company’s market share. The factors that shape those decisions are a tangle of clinical evidence, personal experience, patient preferences, drug cost, and pharmaceutical marketing.
Pharmaceutical companies spent $13.8 billion on advertising and promotion in the U.S. in 2023 alone (across just ten major companies), and a significant share of that spending targets physicians through sales representatives, medical conferences, and sponsored education. Research consistently shows that a doctor’s prescribing habits are influenced not only by a patient’s clinical condition but also by the marketing strategies of the companies whose drugs they prescribe. Variations in physician prescribing patterns have a measurable effect on both patient outcomes and healthcare spending.
Patients as the End User
Patients are the ultimate consumers of pharmaceutical products, but their role as direct customers has been growing. Households now account for about 28% of total national health spending, making them the second-largest source of health spending after the federal government.
Out-of-pocket costs vary dramatically depending on insurance coverage and drug type. For Medicare beneficiaries taking brand-name drugs who reach the catastrophic coverage phase, total out-of-pocket spending is around $3,300 per year, with manufacturers covering another $4,700 through required discount programs. Patients who rely heavily on generic drugs can actually face higher personal costs (up to $8,000) because manufacturer discount programs don’t apply to generics.
Direct-to-consumer advertising has turned patients into active participants in the prescribing process. In the first quarter of 2025, drugmakers spent $729.4 million on TV commercials for just the top ten advertised brands, up from $567.3 million in the same period of 2024. These ads are designed to drive patients into their doctor’s office asking for a specific medication by name, effectively making the patient a customer who generates demand even though they rarely pay the full price.
Research Institutions and Government Labs
A less visible customer base includes academic research institutions and government laboratories. Pharmaceutical companies enter into material transfer agreements, clinical trial agreements, and licensing deals with research organizations like the National Cancer Institute, which holds about 200 active investigational drug applications at any given time. These collaborations give early-stage companies access to clinical infrastructure, while large pharmaceutical firms use them to advance technologies and compounds through development. Each of the top 20 pharmaceutical companies has worked with NCI through some combination of collaborative and licensing agreements. While this segment represents a fraction of total pharmaceutical revenue, it plays a critical role in the pipeline that eventually produces the drugs sold through every other channel.